Recently, it has been established that mutations in BMPR-II, that prevent signalling by this receptor, resulted in reduced levels of apelin in both plasma and endothelial cells from patients with heritable pulmonary arterial hypertension (PAH) [22]. This evidence concerns the gene APLN and pulmonary arterial hypertension.